Turn precision medicine into action
When you’re driven to improve cancer patients’ lives, turn to a leader in oncology clinical trial development.
Through CerbACT, our immuno-oncology Center of Excellence, we empower precision medicine research by applying deep and wide biomarker expertise, translational research, and clinical development strategy.
From our purpose-built lab facility in Taiwan, CerbACT Asia supports I/O drug developers globally with cutting edge technology in FCM, histopathology, immunohistochemistry, and NGS sequencing, to turn precision medicine into action.
Expert development and validation of custom flow cytometry assay panels for your clinical trials
Histopathology and immunohistochemistry (IHC)
Exploratory and in vitro diagnostic testing, histopathology, and advanced IHC analysis
Peripheral blood mononuclear cell (PBMC) and cell isolations
Capacity for any size project
NGS testing for patient diagnostics
CerbACT is a joint venture between Cerba Research and ACT Genomics, developed to meet the needs of IO drug developers. A synergistic combination of expertise and capabilities to solve precision medicine challenges by advancing your research with a new platform combining deep scientific expertise and technical capabilities. For biotech, pharmaceutical, government, and non-government organizations, CerbACT turns precision medicine innovation into action.
Explore the CerbACT Asia Laboratory
Watch this video for a grand tour of our facility in Taipei in 360° view and discover a short overview of the instruments and technology present to support you in your Immuno-oncology research.
Reach out to our experts and discover how we can help you transform your research and advance health!Contact Us